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abnormal cardiac valves. There are also few clinical
trials on nonathletes with aortic or mitral valve dis-
ease. Consequently, recommendations for athletic
participation in people with these conditions are
based on cohort analyses of nonathletic subjects and
consensus opinion.
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TABLE 1
Severity of Aortic Stenosis by Doppler
Echocardiography
Severity
Jet Velocity,
m/s
Mean Gradient,
mm Hg
Aortic Valve Area,
cm2
Mild <3 <20 >1.5
Moderate 3–4 20–40 1–1.5
Severe >4 >40 <1.0
Reprinted from Nishimura et al (1). Copyright ª 2014, American Heart Association, Inc.
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2386normal left ventricular (LV) systolic function. Stage C
designates asymptomatic patients with severe valvular
heart disease with evidence of preserved systolic function
(stage C1) or LV dysfunction (C2), and stage D designates
patients with symptomatic severe valvular heart disease
with or without LV dysfunction. Eligibility for competitive
sports is a pertinent issue for people with valvular heart
disease in stages A, B, and C, whereas symptomatic pa-
tients in stage D are not candidates for competition and
under most circumstances should be referred for valve
replacement or repair. Athletic competition is also a rele-
vant issue in asymptomatic patients who have undergone
successful valve surgery.
AORTIC VALVE DISEASE
Aortic valve disease is usually caused by degenerative
changes in a bicuspid or tricuspid aortic valve. Calciﬁca-
tion of trileaﬂet aortic valves is an increasingly common
cause of aortic stenosis (AS) in middle-aged and elderly
people because of increased longevity in the United States
and other developed nations. Bicuspid aortic valves occur
in 1.5% to 2.0% of the population and thus are common
ﬁndings in young athletes (2). In developed countries,
there is a very low incidence of rheumatic aortic valve
disease, but this pathogenesis predominates in athletes
from developing nations. Additional causes of outﬂow
obstruction can be nonvalvular and include subvalvular
and supravalvular AS, both produced by cardiomyopa-
thies and congenital abnormalities in the left ventricle
and ascending aorta, as discussed in other sections of this
document. Primary diseases of the aorta are common
causes of aortic valve regurgitation (AR) (1), and this
pathogenesis should be considered in athletes presenting
with AR.
Aortic Stenosis
AS is a well-known cause of exertion-related sudden
cardiac death but is responsible for <4% of sudden deaths
in young athletes (3). The severity of AS is best evaluated
with the combination of the history, physical examina-
tion, and Doppler echocardiography. A history of
decreasing exercise tolerance, exertional dyspnea, or
exercise-induced angina in an athlete with a systolic
murmur should raise the possibility of severe AS. A
decreased volume and delayed upstroke of the carotid
pulse, as well as a greater intensity and duration of the
systolic murmur, also suggest clinically important AS.
Assessment of congenital AS in children and adoles-
cents and recommendations for participation in athletics
in these age groups are discussed in the Task Force 4
report (4) on congenital heart disease in this document.
The following discussion pertains to recommendations in
fully grown athletes in late adolescence and adulthood.Doppler echocardiography is the standard method to
assess AS (1), and its severity is graded as shown in
Table 1.
Clinicians should combine features of the history,
physical examination, and echocardiogram in evaluating
the severity of AS, as well as integrating the various
echocardiographic measures of jet velocity, mean
gradient, and calculated valve area, because each has
limitations. In young patients with abnormal aortic
valves, it is also important to assess the size and
morphology of the ascending aorta to exclude concomi-
tant aortopathy, as discussed below. Athletes with mild
or moderate AS (stage B) should be evaluated yearly,
because the valve can narrow progressively. Exercise
testing with electrocardiographic and blood pressure
monitoring is useful in evaluating ostensibly asymptom-
atic athletes with AS because it may reveal unexpectedly
low exercise tolerance, exercise hypotension, or electro-
cardiographic abnormalities that may alter the exercise
recommendations. Doppler echocardiography can under-
estimate the severity of the aortic valve gradient, so
further evaluation is warranted in athletes with Doppler
evidence of mild or moderate AS who have symptoms
or LV hypertrophy.Evaluation
Athletes with bicuspid aortic valves without stenosis
(stage A) should undergo yearly physical examinations for
detection of new onset of heart murmurs. Athletes with
mild to moderate AS (stage B) should have a yearly his-
tory, physical examination, and Doppler echocardiogram
to evaluate disease severity. Exercise testing should be
performed in athletes with mild and moderate AS to
ensure that their effort tolerance is commensurate with
the proposed athletic activity and that they do not
develop exercise hypotension or electrocardiographic
evidence of ischemia.
Recommendations
1. Athletes with AS should be evaluated yearly to
determine whether sports participation can continue
(Class I; Level of Evidence C).
J A C C V O L . 6 6 , N O . 2 1 , 2 0 1 5 Bonow et al.
D E C E M B E R 1 , 2 0 1 5 : 2 3 8 5 – 9 2 Competitive Athletes: Valvular Heart Disease
23872. Athletes with mild AS (stage B) and a normal maximal
exercise response can participate in all sports
(Class IIa; Level of Evidence C).
3. Athletes with moderate AS (stage B) can participate in
low and moderate static or low and moderate dynamic
competitive sports (classes IA, IB, and IIA) if exercise
tolerance testing to at least the level of activity
achieved in competition and the training regimen
demonstrates satisfactory exercise capacity without
symptoms, ST-segment depression, or ventricular
tachyarrhythmias, and with a normal blood pressure
response (Class IIa; Level of Evidence C).
4. Asymptomatic athletes with severe AS (stage C)
should not participate in competitive sports, with the
possible exception of low-intensity (class IA) sports
(Class III; Level of Evidence C).
5. Symptomatic patients with AS (stage D) should not
participate in competitive sports (Class III; Level of
Evidence C).TABLE 2 Left Ventricular Dimensions in Elite Athletes
Men Women
MeanSD Upper Limit MeanSD Upper Limit
LVESD, mm* 38.23.2 49 32.92.9 38
LVEDD, mm* 58.83.4 70 52.23.2 60
LVEDD, mm† 54.22.0 66 48.93.8 66
LVEDD/BSA, mm/m2† 28.12.3 35.3 29.82.5 40.8
LVEDD/height, mm/m† 30.12.1 36.8 29.31.9 35.9
BSA indicates body surface area; LVEDD, left ventricular end-diastolic dimension;
and LVESD, left ventricular end-systolic dimension.
*Data from 114 Olympic athletes (89 men, 25 women) (7).
†Data from 1338 elite athletes (738 men, 600 women) (8).Aortic Regurgitation
The common causes of chronic AR include bicuspid aortic
valve disease, congenital connective tissues disorders
such as Marfan syndrome, rheumatic heart disease, and
idiopathic or hypertensive dilation of the ascending aorta
(1). Chronic AR is usually asymptomatic and well tolerated
for years, but when severe, it produces a gradual increase
in LV dimensions. The diagnosis during the asymptomatic
stages of AR (stages B and C) is suggested on physical
examination by a wide arterial pulse pressure, a diastolic
murmur heard along the sternal border, or a systolic
outﬂow murmur related to the increased forward stroke
volume. Doppler echocardiography is useful in conﬁrming
the diagnosis and grading the severity of AR (1,5). AR
produces both pressure and volume loading of the LV but
is usually well tolerated for decades, with normal LV
systolic performance despite the increased LV volume
until the LV cannot tolerate further increases in the
volume overload.
It is often difﬁcult to differentiate the LV dilatation
produced in athletes by exercise training from the dila-
tation produced by chronic severe AR in its early and
advanced stages. Therefore, assessment of LV enlarge-
ment in highly trained athletes with known or suspected
AR must take this issue into consideration. Progressively
severe AR can result in LV volumes that exceed the
normal physiological responses to athletic training, but
there is overlap in LV volume encountered in normal
athletes and patients with AR. Up to 45% of trained male
athletes have LV end-diastolic dimension (LVEDD) >55
mm (6,7), but only 14% of even elite male athletes have
LVEDD >60 mm, and LVEDD rarely exceeds 70 mm (6,7).
LVEDD >55 mm occurs in <10% of elite women athletesand is >60 mm in only 1% (8). Hence, athletes with severe
AR and LVEDD exceeding these values have a high like-
lihood that severe AR is contributing to the LV dilation
and should be evaluated carefully for decreasing exercise
tolerance and absence of ventricular augmentation with
exercise. Similarly, LV end-systolic dimension (LVESD)
may also be increased with athletic training. Among elite
athletes, the upper limit of LVESD is 49 mm for men and
38 mm for women (7). It may be helpful to normalize
LVEDD and LVESD for body size (9), because larger ath-
letes have larger ventricular volumes. Data indexed for
body surface area and height in athletes are available for
LVEDD (6,8) but not LVESD. The reported upper limit of
LVEDD indexed for body surface area is 35.3 mm/m2 for
men and 40.8 mm/m2 for women (8). Values for LVEDD
and LVESD for elite athletes as reported by Pelliccia et al
(7,8) are summarized in Table 2.
The LV ejection fraction response to exercise is also
maintained in patients with chronic AR until there is se-
vere LV dilation (10). An ejection fraction <50% at rest in
an athlete with severe AR indicates LV decompensation.
Serial assessment of the LVESD is valuable in assessing
the progressive effects of severe AR in those with normal
LV ejection fractions. In patients with severe AR, the 2014
American Heart Association/American College of Cardi-
ology “Guideline for the Management of Patients With
Valvular Heart Disease” (1) deﬁnes preserved systolic
function (stage C1) as LV ejection fraction $50% and
LVESD #50 mm or indexed LVESD #25 mL/m2.
Evaluation
Athletes with AR should undergo a yearly history and
physical examination with Doppler echocardiography.
Exercise testing to at least the level of activity achieved in
competition and the training regimen is helpful in con-
ﬁrming asymptomatic status and assessing blood pressure
responses. The usefulness of assessing LV function with
exercise in athletes has not been established. Patients
with AR often have underlying bicuspid aortic valves.
In these patients, it is important to also assess the
morphology of the aortic root and ascending aorta to rule
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participation for athletes with bicuspid aortic valves and
dilated aortas are provided in the Task Force 7 recom-
mendations of this report (11).
Recommendations
1. Athletes with AR should be evaluated annually to
determine whether sports participation can continue
(Class I; Level of Evidence C).
2. Exercise testing to at least the level of activity
achieved in competition and the training regimen is
helpful in conﬁrming asymptomatic status in athletes
with AR and assessing blood pressure responses
(Class I; Level of Evidence C).
3. Athletes with mild to moderate degrees of AR (stage
B) with normal LV ejection fraction and no or mild LV
dilatation can participate in all competitive sports if
they have normal exercise tolerance on exercise
testing (Class I; Level of Evidence C).
4. Athletes with mild to moderate degrees of AR with
normal LV ejection fraction and moderate LV dilata-
tion (LVESD <50 mm [men], <40 mm [women], or <25
mm/m2 [either sex]) can reasonably participate in all
competitive sports if they have normal exercise
tolerance on exercise testing (Class IIa; Level of Evi-
dence C).
5. It may be reasonable for athletes with severe AR, LV
ejection fraction ‡50% (stage C1), and LVESD <50
mm (men), <40 mm (women), or <25 mm/m2 (either
sex) to participate in all competitive sports if they
have normal exercise tolerance, and Doppler echo-
cardiography indicates no progression of AR severity
or severity of LV dilatation (Class IIb; Level of
Evidence C).
6. It may be reasonable for athletes with AR and aortic
dimensions of 41 to 45 mm to participate in sports
with low risk of bodily contact (Class IIb; Level of
Evidence C).
7. Athletes with severe AR and symptoms (stage D), LV
systolic dysfunction with ejection fraction <50%
(stage C2), LVESD >50 mm or >25 mm/m2 (stage C2), or
severe increase in LVEDD (>70 mm or ‡35.3 mm/m2
[men], >65 mm or ‡40.8 mm/m2 [women]) should not
participate in competitive sports (Class III; Level of
Evidence C).Bicuspid Aortic Valves
Bicuspid aortic valve is present in 1% to 2% of the popu-
lation (1,2) and is the marker of connective tissue abnor-
malities that affect both the aortic valve and aorta. That
patients with bicuspid aortic valves are at increased risk
for AS and AR is well known, but these patients are also
at increased risk for aortic enlargement and aorticdissection, although the absolute risk for these events is
quite small (1,12), and it is not known whether restriction
of physical activity limits the risk or the rate of aortic
enlargement or dissection.
Evaluation
Patients with bicuspid aortic valves should undergo
echocardiography to evaluate both aortic valve function
and the size of the aortic sinuses and ascending aorta.
The Task Force 7 report (11) in this document contains
recommendations for sports participation in athletes with
bicuspid aortic valves and dilated aortas.
MITRAL VALVE DISEASE
Mitral Stenosis
The pathogenesis of mitral stenosis (MS) is almost always
rheumatic. Most patients with signiﬁcant MS will be suf-
ﬁciently symptomatic during exercise that participation
in competitive sports is not an issue, but patients with
mild to moderate MS may be asymptomatic even with
strenuous exercise. MS rarely causes sudden death;
however, exercise (with an increase in heart rate and
cardiac output) can cause sudden marked increases in
pulmonary capillary and pulmonary artery pressures, at
times resulting in sudden acute pulmonary edema (13).
Furthermore, the long-term effect of repeated exertion-
related increases in pulmonary artery wedge and pulmo-
nary artery pressures on the lungs or right ventricle is
unknown, nor is the effect of even periodic strenuous
exercise on the likelihood of developing atrial ﬁbrillation.
When atrial ﬁbrillation occurs, even patients with mild
MS must receive anticoagulation therapy. The above
considerations must be understood by the patient and the
family in considering participation in strenuous com-
petitive activity. Another problem associated with MS is
systemic embolization, which occurs most commonly in
the presence of atrial ﬁbrillation, but there is no evidence
that this potential complication is provoked by strenuous
exercise.
Clues regarding the hemodynamic severity of MS may
often be obtained from the history and physical exam-
ination, but accurate noninvasive assessment of severity
requires 2-dimensional and Doppler echocardiography
in the majority of patients. MS is categorized as severe
when the mitral valve area is <1.5 cm2, which corre-
sponds to a mean transmitral gradient of 5 to 10 mm Hg
at normal resting heart rates (1). The mean pressure
gradient is highly dependent on the transvalvular ﬂow
and diastolic ﬁlling period and will vary greatly with
increases in heart rate during exercise. A mean trans-
mitral gradient >15 mm Hg or pulmonary artery wedge
pressure >25 mm Hg during exercise is indicative or
signiﬁcant MS.
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In patients with MS and minimal or no symptoms who
wish to engage in competitive sports, exercise stress
testing should be performed to at least the level of activity
that approximates the exercise demands of the sport,
particularly when there is a question as to the severity of
the MS. In addition, pulmonary artery systolic pressure
during exercise can be estimated noninvasively by
Doppler echocardiography and may be helpful in making
a decision as to how much activity is safe, even if the
severity of MS in an individual patient is estimated to be
only mild (1).
Recommendations
1. Athletes with MS should be evaluated annually to
determine whether sports participation can continue
(Class I; Level of Evidence C).
2. Exercise testing to at least the level of activity ach-
ieved in competition and the training regimen is use-
ful in conﬁrming asymptomatic status in patients with
MS (Class I; Level of Evidence C).
3. It is reasonable for athletes with mild MS (mitral valve
area >2.0 cm2, mean gradient <10 mm Hg at rest) in
sinus rhythm to participate in all competitive sports
(Class IIa; Level of Evidence C).
4. Athletes with severe MS (mitral valve area <1.5 cm2) in
either sinus rhythm or atrial ﬁbrillation should not
participate in competitive sports, with the possible
exception of low-intensity (class IA) sports (Class III;
Level of Evidence C).
5. Patients with MS of any severity who are in atrial
ﬁbrillation or have a history of atrial ﬁbrillation, who
must receive anticoagulation therapy, should not
engage in any competitive sports involving the risk
of bodily contact (Class III; Level of Evidence C).Mitral Regurgitation
Mitral regurgitation (MR) has a variety of possible causes,
the most common of which in an athletic population is
mitral valve prolapse (myxomatous mitral valve disease).
Other common causes are rheumatic heart disease,
infective endocarditis, and connective tissue diseases
(such as Marfan syndrome). Secondary forms of MR can
develop in patients with coronary artery disease and
dilated cardiomyopathy because of tethering of the mitral
leaﬂets and restricted leaﬂet closure. The recommenda-
tions outlined in this section are for athletes with primary
valvular MR rather than MR secondary to coronary artery
disease or other conditions that cause LV dilation or sys-
tolic dysfunction.
MR is detected by the characteristic systolic murmur,
conﬁrmed and quantiﬁed by Doppler echocardiography
(1,5). The severity of the MR is related to the magnitudeof the regurgitant volume, which results in LV dilation
and increases in left atrial pressure and volume. The
majority of people with mild or moderate MR are
asymptomatic (stage B). The increased LV diastolic
volume enhances total LV stroke volume enough to
accommodate the regurgitant volume and to maintain
the forward stroke volume within normal limits. The
low impedance presented by regurgitation into the left
atrium unloads the left ventricle during ventricular
systole, such that measures of LV pump function, such
as ejection fraction, tend to overestimate true myocar-
dial performance (14). For purposes of this discussion,
LV systolic dysfunction in subjects with MR is deﬁned
as LV ejection fraction <60% or LVESD >40 mm (1). As
with AR, the distinction between LV dilation caused by
athletic training versus that caused by severe MR is
difﬁcult when the LVEDD is <60 mm (or <40 mm/m2).
However, LVEDD measurements >60 mm strongly sug-
gest the presence of severe MR and perhaps the need
for surgical mitral valve repair and thus warrant further
investigation.
In general, exercise produces no signiﬁcant change or
a mild decrease in the regurgitant fraction because of
reduced systemic vascular resistance. However, patients
with elevation of heart rate (increased systolic ejection
time per minute) or blood pressure with exercise may
manifest marked increases in regurgitant volume and
pulmonary capillary pressures.Evaluation
Athletes with MR should undergo yearly physical exami-
nations, Doppler echocardiograms, and exercise stress
testing to at least the level of activity that approximates
the exercise demands of the sport. In addition, pulmonary
artery systolic pressure during exercise can be estimated
noninvasively by Doppler echocardiography and may be
helpful in making a decision as to how much activity is
safe, particularly in athletes with greater severity of MR
(1). In patients with MR secondary to previous infective
endocarditis or ruptured chordae, the valve tissues
theoretically could be further damaged or torn by marked
sustained increases in LV systolic pressure, and thus, the
recommendations below should be tempered in patients
with these mechanisms of MR.
Recommendations
1. Athletes with MR should be evaluated annually to
determine whether sports participation can continue
(Class I; Level of Evidence C).
2. Exercise testing to at least the level of activity achi-
eved in competition and the training regimen is useful
in conﬁrming asymptomatic status in patients with
MR (Class I; Level of Evidence C).
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rhythm with normal LV size and function and with
normal pulmonary artery pressures (stage B) can
participate in all competitive sports (Class I; Level of
Evidence C).
4. It is reasonable for athletes with moderate MR in sinus
rhythm with normal LV systolic function at rest and
mild LV enlargement (compatible with that which may
result solely from athletic training [LVEDD <60 mm
or <35 mm/m2 in men or <40 mm/m2 in women])
to participate in all competitive sports (stage B)
(Class IIa; Level of Evidence C).
5. Athletes with severe MR in sinus rhythm with normal
LV systolic function at rest and mild LV enlargement
(compatible with that which may result solely from
athletic training [LVEDD <60 mm or <35.3 mm/m2 in
men or <40 mm/m2 in women]) can participate in
low-intensity and some moderate-intensity sports
(classes IA, IIA, and IB) (stage C1) (Class IIb; Level of
Evidence C).
6. Athletes with MR and deﬁnite LV enlargement
(LVEDD ‡65 mm or ‡35.3 mm/m2 [men] or ‡40 mm/m2
[women]), pulmonary hypertension, or any degree of
LV systolic dysfunction at rest (LV ejection frac-
tion <60% or LVESD >40 mm) should not participate in
any competitive sports, with the possible exception
of low-intensity class IA sports (Class III; Level of
Evidence C).
7. Athletes with a history of atrial ﬁbrillation who
are receiving long-term anticoagulation should not
engage in sports involving any risk of bodily contact
(Class III; Level of Evidence C).ATHLETIC PARTICIPATION AFTER
CARDIAC VALVE SURGERY
Despite advances in cardiac surgery, the long-term mor-
tality after valve replacement surgery is greater than
that of a normal population of similar age. A transvalvular
gradient of varying severity is present in most patients
after valve replacement, which may be aggravated
during exercise (1,15). Moreover, after implantation of a
mechanical prosthesis, which is common in young patientsrequiring valve replacement, chronic anticoagulation is
required. These considerations are important in deter-
mining an athlete’s suitability for competition after valve
replacement. In patients who have undergone aortic
valve repair or, more commonly, mitral valve repair, a
different set of issues regarding the risks of physical
trauma during athletic competition must be considered.
In assessing the athlete’s capacity for physical activity
after valve surgery, exercise stress testing to at least
the level of activity performed in the competitive sport
is valuable. In some cases, assessment of prosthetic
valve function during exercise will also provide useful
information.Recommendations
1. It is reasonable for athletes with aortic or mitral bio-
prosthetic valves, not taking anticoagulant agents,
who have normal valvular function and normal LV
function to participate in low-intensity and some
moderate-intensity competitive sports (classes IA, IB,
IC, and IIA) (Class IIa; Level of Evidence C).
2. Athletes with aortic or mitral mechanical prosthetic
valves taking anticoagulant agents with normal
valvular function and normal LV function can
reasonably participate in low-intensity competitive
sports if there is low likelihood of bodily contact
(classes IA, IB, and IIA) (Class IIa; Level of
Evidence C).
3. It is reasonable for patients with MS who have un-
dergone successful percutaneous mitral balloon
valvotomy or surgical commissurotomy to partici-
pate in competitive sports based on the residual
severity of the MS or MR and pulmonary artery
pressures at rest and with exercise (Class IIa; Level
of Evidence C).
4. Athletes who have undergone mitral valve repair
for MR or surgical aortic valve repair, have no or
mild residual AR or MR, and have normal LV sys-
tolic function may be considered for participation
in sports at the discretion of the managing physi-
cian if there is low likelihood of bodily contact
(classes IA, IB, and IIA) (Class IIa; Level of
Evidence C).
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